Zai Lab Limited — FY2020 Form 10-K
Reporting period: Year ended December 31, 2020; filed March 1, 2021. This is an annual report, not a quarterly filing, and the supplied filing text does not provide standalone fourth-quarter results. Financial figures below are in U.S. dollars unless stated otherwise.
Business context
Zai Lab is a commercial-stage biopharmaceutical company focused on oncology, autoimmune disorders and infectious diseases, with operations primarily in Greater China and a presence in the United States. ZEJULA and Optune were its two commercialized products. The filing described a pipeline of 21 candidates, including 11 late-stage programs; QINLOCK and NUZYRA had received NMPA Priority Review.
Financial and operating metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net revenue | $49.0 million | $13.0 million |
| Cost of sales | $16.7 million | $3.7 million |
| Approximate gross margin | 65.8% | 71.1% |
| Research and development expense | $222.7 million | $142.2 million |
| Selling, general and administrative expense | $111.3 million | $70.2 million |
| Loss from operations | $(301.8) million | $(203.2) million |
| Net loss | $(268.9) million | $(195.1) million |
| Basic and diluted loss per share | $(3.46) | $(3.03) |
| Net cash used in operating activities | $(216.1) million | $(191.0) million |
Product revenue was $32.1 million from ZEJULA, $16.4 million from Optune and $0.4 million from other products. Reported 2020 net revenue reflected $8.4 million of rebates and sales returns. Gross margin above is approximate, calculated from reported net revenue and cost of sales.
At year-end, cash and cash equivalents were $442.1 million, restricted cash was $0.7 million and short-term investments were $744.7 million, totaling approximately $1.19 billion. Current assets were $1.22 billion and current liabilities $98.0 million. Short-term borrowings were nil; total liabilities were $128.3 million, including operating lease liabilities. Investing activities used $554.8 million, principally reflecting net purchases of short-term investments; financing activities provided $1.13 billion, primarily from equity offerings and the Hong Kong listing.
Material changes versus the prior year
- Revenue increased approximately 277%, reflecting broader commercialization of ZEJULA and Optune. ZEJULA revenue rose to $32.1 million from $6.6 million; Optune revenue rose to $16.4 million from $6.4 million.
- Gross margin declined approximately 5.3 percentage points. ZEJULA’s inclusion in China’s National Reimbursement Drug List (NRDL) in December 2020 improved access but the company said the resulting price reductions could weigh on revenue.
- R&D expense increased 56.6%, with licensing fees rising to $108.2 million from $58.7 million and increased clinical-development spending. SG&A increased 58.5%, reflecting hiring, commercialization and public-company costs.
- Net loss widened by $73.8 million. Other income rose to $29.1 million from $0.9 million, primarily due to increased government subsidies and foreign-exchange gain; it partly offset the larger operating loss.
- Cash and short-term investments increased substantially, supported by 2020 equity financing. Shares issued and outstanding rose to 87.8 million from 68.2 million at year-end 2019.
Outlook, commentary and risks
- Management provided no specific revenue, earnings or product-launch guidance. It expected continued losses and substantial R&D and commercialization spending. Based on its operating plan, management said available cash, cash equivalents and short-term investments were expected to fund operating expenses and capital expenditures for at least 12 months after the financial statements were issued; this estimate depends on assumptions and future spending.
- Licensing and collaboration agreements carry upfront, milestone and royalty costs. The filing disclosed up to approximately $2.51 billion in potential future milestone payments across agreements; these are contingent on specified events, are not fixed or determinable, and are not recorded as current balance-sheet debt.
- ZEJULA was added to the NRDL, but negotiated reimbursement and pricing may reduce realized prices. Revenue also remains concentrated among distributors: the five largest customers represented 48.6% of revenue in 2020, and the largest represented 27.5%.
- COVID-19 had caused some difficulty reaching patients and delays in clinical-trial enrollment; management reported no material delay to NDA submissions or acceptances and only minimal overall disruption to commercialization at the time of filing. Future effects remained uncertain.
- Pipeline, regulatory, safety, manufacturing and third-party supply risks are significant. The filing noted an FDA partial clinical hold affecting new enrollment in Regeneron’s odronextamab lymphoma trials, pending protocol changes to reduce severe cytokine-release syndrome.
- Other material risks include China-U.S. geopolitical and capital-market tensions, evolving Chinese data and human-genetic-resource rules, foreign-exchange controls, intellectual-property dependence on licensors and uncertainty about PCAOB inspection access for the auditor’s China-based audit work. The company reported no material pending legal proceedings and stated that internal control over financial reporting was effective.
Important facts for investors to verify
- Whether ZEJULA and Optune sales growth can offset NRDL price reductions, rebates and the lower reported gross margin.
- Operating cash burn, the composition and accessibility of cash and time deposits, and the assumptions behind the stated 12-month liquidity outlook.
- The timing and potential cash impact of licensing milestones, cost-sharing payments and royalties, including agreements entered into after year-end.
- Clinical progress and regulatory timelines for QINLOCK, NUZYRA and other late-stage programs, including the status and implications of the odronextamab enrollment pause.
- Distributor and customer concentration, product supply continuity, and the company’s exposure to China-related audit-access, data-regulation and geopolitical risks.